Stockscreener 앱 받기
5.90
3.96%
0.225
시간 외 거래:
6.19
0.29
+4.92%
전일 마감가:
$5.675
열려 있는:
$5.56
하루 거래량:
510.54K
Relative Volume:
0.62
시가총액:
$392.44M
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-3.2418
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
+3.33%
1개월 성능:
-5.60%
6개월 성능:
-44.86%
1년 성능:
-66.57%
1일 변동 폭
$5.44
$6.14
1주일 범위
$5.37
$6.14
52주 변동 폭
$3.91
$21.25
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
명칭
Eyepoint Pharmaceuticals Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
EYPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
5.90 | 392.44M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
Pars Planitis Market Set to Grow Substantially Through 2032, - openPR.com
EyePoint (EYPT) Offers Stock Options as Inducement for New Hires | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Expands Team with Strategic Stock Options Package Worth $370K - Stock Titan
How the (EYPT) price action is used to our Advantage - news.stocktradersdaily.com
Nano Silicon Drug Delivery Platform Market to Witness Massive - openPR.com
Ex-Dividend Date Nearing for These 10 Stocks – Week of April 7, 2025 - The Globe and Mail
EyePoint Pharmaceuticals' US$84m Market Cap Fall Books Insider Losses - simplywall.st
EyePoint Pharmaceuticals at RBC Conference: Insights on Duravu’s Promise By Investing.com - Investing.com Canada
Working At Eyepoint - EyePoint Pharmaceuticals
Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation - Yahoo Finance
Long Term Trading Analysis for (EYPT) - news.stocktradersdaily.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times
EyePoint's CEO Takes Center Stage: Key Updates Coming at RBC Ophthalmology Conference - Stock Titan
What is Chardan Capital’s Estimate for EYPT FY2026 Earnings? - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Bank of New York Mellon Corp - Defense World
3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets
(EYPT) Investment Report - news.stocktradersdaily.com
Mizuho maintains EyePoint stock Outperform with $30 target By Investing.com - Investing.com Australia
Mizuho maintains EyePoint stock Outperform with $30 target - Investing.com India
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India
StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to “Sell” - Defense World
EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada
Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World
Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Re - GuruFocus.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
Rhumbline Advisers Purchases 12,443 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Chardan Capital Reiterates “Buy” Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews - Benzinga
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating - TipRanks
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target - Investing.com India
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call Transcript - Insider Monkey
Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k - Yahoo Finance
EyePoint Pharmaceuticals: Q4 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highli - GuruFocus.com
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... By GuruFocus - Investing.com Canada
EyePoint Pharmaceuticals Reports 2024 Financial Results - TipRanks
EyePoint Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss - Investing.com India
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Eyepoint Pharmaceuticals Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):